The safety and pharmacokinetics of metformin in patients with chronic liver disease

The FDA approved ‘label’ for metformin lists hepatic insufficiency as a risk for lactic acidosis. Little evidence supports this warning.

[1]  M. Rutter,et al.  Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. , 2018, Health technology assessment.

[2]  C. Zauner,et al.  Acid-base disorders in liver disease. , 2017, Journal of hepatology.

[3]  Matthew J. Crowley,et al.  Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease , 2017, Annals of Internal Medicine.

[4]  R. Day,et al.  The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus. , 2015, British journal of clinical pharmacology.

[5]  T. Therneau,et al.  Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes , 2014, Hepatology.

[6]  M. Adeva-Andany,et al.  Comprehensive review on lactate metabolism in human health. , 2014, Mitochondrion.

[7]  F. Bendtsen,et al.  Lactate metabolism in chronic liver disease , 2013, Scandinavian journal of clinical and laboratory investigation.

[8]  A. R. Rätz Bravo,et al.  Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations , 2013, European Journal of Clinical Pharmacology.

[9]  R. Day,et al.  The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis , 2013, Drug Safety.

[10]  R. Day,et al.  Population Pharmacokinetics of Metformin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus: Simulation of Doses According to Renal Function , 2013, Clinical Pharmacokinetics.

[11]  J. D. del Campo,et al.  Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy , 2012, PloS one.

[12]  R. Day,et al.  Metformin therapy in patients with chronic kidney disease , 2012, Diabetes, obesity & metabolism.

[13]  Stephen Colagiuri,et al.  Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement , 2012, The Medical journal of Australia.

[14]  G. Bray,et al.  Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study , 2012, Diabetes Care.

[15]  E. Vicaut,et al.  Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. , 2011, The Journal of clinical endocrinology and metabolism.

[16]  R. Day,et al.  Clinical Pharmacokinetics of Metformin , 2011, Clinical pharmacokinetics.

[17]  B. Astor,et al.  Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study , 2010, International journal of epidemiology.

[18]  M. L. de la Mata,et al.  Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa‐2a plus ribavirin , 2009, Hepatology.

[19]  J. Hoofnagle,et al.  Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis , 2009, Alimentary pharmacology & therapeutics.

[20]  G. Jung,et al.  Model for end-stage liver disease , 2008, Der Chirurg.

[21]  Shari Bolen,et al.  Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus , 2007, Annals of Internal Medicine.

[22]  V. Alves,et al.  Combination of N‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[23]  M. Matsuda,et al.  Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation , 2007, Diabetes.

[24]  W. Kim,et al.  The model for end‐stage liver disease (MELD) , 2007, Hepatology.

[25]  Keith G. Tolman,et al.  Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease , 2007 .

[26]  B. Phypers,et al.  Lactate physiology in health and disease , 2006 .

[27]  J. Kraut,et al.  Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  H. El‐Serag,et al.  Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. , 2004, Gastroenterology.

[29]  A. Holstein,et al.  Clinical implications of hepatogenous diabetes in liver cirrhosis , 2002, Journal of gastroenterology and hepatology.

[30]  Marco Zoli,et al.  Metformin in non-alcoholic steatohepatitis , 2001, The Lancet.

[31]  A. Morris,et al.  Contraindications to metformin therapy in patients with Type 2 diabetes—a population‐based study of adherence to prescribing guidelines , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[32]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[33]  G. Reaven,et al.  Plasma lactate concentration in obesity and type 2 diabetes. , 1993, Diabete & metabolisme.

[34]  P. Marchetti,et al.  Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients. , 1990, Diabete & metabolisme.

[35]  P. Jansson,et al.  Evidence for lactate production by human adipose tissue in vivo , 1990, Diabetologia.

[36]  M. Eggstein,et al.  Definition of clinically relevant lactic acidosis in patients with internal diseases. , 1983, American journal of clinical pathology.

[37]  H Connor,et al.  Metformin kinetics in healthy subjects and in patients with diabetes mellitus. , 1981, British journal of clinical pharmacology.

[38]  P. Woll,et al.  Lactate elimination in man: effects of lactate concentration and hepatic dysfunction , 1979, European journal of clinical investigation.

[39]  G. Franceschini,et al.  Disposition of metformin (N,N‐dimethylbiguanide) in man , 1978, Clinical pharmacology and therapeutics.

[40]  L. Hermansen,et al.  Production and removal of lactate during exercise in man. , 1972, Acta physiologica Scandinavica.

[41]  A. Blumentals,et al.  Acid-base disturbances in patients with cirrhosis of the liver. , 1967, Medicine.

[42]  J. Lalau,et al.  Establishment of a Database of Metformin Plasma Concentrations and Erythrocyte Levels in Normal and Emergency Situations , 2011, Clinical drug investigation.

[43]  P. Marathe,et al.  Steady-State Pharmacokinetics of a Novel Extended-Release Metformin Formulation , 2005, Clinical pharmacokinetics.

[44]  K. Johansen.  Efficacy of metformin in the treatment of NIDDM. Meta-analysis. , 1999, Diabetes care.

[45]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .